Overview of Epilat Retard

Property	Description
Active ingredient	Nifedipine
Form	Sustained-Release Tablet (Retard)
Pharmacological class	Calcium Channel Blocker (CCB)
General purpose	Management of vascular tone and systemic resistance
Origin	Synthetic Dihydropyridine derivative

What Type of Medicine is Epilat Retard?

Epilat Retard is a prescription-only medication featuring Nifedipine, a synthetic compound that belongs to the Calcium Channel Blocker (CCB) pharmacological class. Nifedipine is a dihydropyridine derivative that acts as a calcium ion antagonist, selectively influencing the muscle cells in blood vessel walls. This classification is clinically recognized for its role in the long-term management of chronic cardiovascular conditions requiring consistent vascular support in adult patients.

Composition and The Significance of the Retard Formulation

The core of Epilat Retard is its single-ingredient product status, defined by the presence of Nifedipine and specialized pharmaceutical excipients. The medication is an Oral Sustained-Release Tablet, identified by the term “Retard,” which confirms a modified-release delivery system. This design ensures the active compound is released gradually over a sustained timeframe, offering a prolonged action profile. The sustained-release formulation minimizes rapid concentration changes associated with immediate-release tablets, helping to maintain a stable, therapeutic effect.

What is the General Therapeutic Purpose of Nifedipine?

The general therapeutic purpose of Nifedipine is to support cardiovascular function through active vascular relaxation (vasodilation) and the consequent reduction of peripheral vascular resistance. By blocking calcium influx, the medicine prevents the sustained contraction of arterial wall muscles. This action decreases the systemic resistance against which the heart must pump, contributing fundamentally to the reduction of blood pressure and ensuring adequate blood flow. The medicine is commonly used in scenarios requiring consistent daily control over blood pressure and vascular tone.

Regulatory References

NIH StatPearls: Nifedipine

What side effects are possible with Epilat Retard?

Possible side effects and safety information

The safety profile for Nifedipine sustained-release (Epilat Retard) is documented in official regulatory sources, classifying potential effects primarily by frequency and the body system affected. These classifications are used to communicate the medicine’s risk profile in a medically grounded manner.

Frequency-Classified Adverse Reactions

The most frequently reported effects are often linked to the medicine's vascular action. These include:

Common (may affect up to 1 in 10 people): Headache, Peripheral Edema (swelling of the ankles or legs), Flushing (warmth or redness), and Constipation.
Uncommon (may affect up to 1 in 100 people): Dizziness, Palpitations, Hypotension (low blood pressure), Gastrointestinal pain, Dry mouth, and Transient increases in liver aminotransferases.

Serious Adverse Reactions and System-Organ Effects

Adverse reactions are grouped by System-Organ Class (SOC) in regulatory documents, including Vascular, Nervous System, and Gastrointestinal Disorders. Serious Adverse Reactions, though rare, are officially documented and include Excessive Hypotension, the risk of Increased Angina and/or Myocardial Infarction (particularly upon initiation or dose increase), severe Allergic Reactions (e.g., Angioedema), and Gastrointestinal Obstruction related to the sustained-release tablet matrix.

Safety Considerations and Exposure Patterns

Specific safety notes are included for certain patient groups. For Hepatic Impairment, caution is required as the drug's effects may be amplified. The safety and efficacy in children under 18 years have not been established. Furthermore, safety documents note that effects such as Hypotension and Syncope are more likely to occur during initial treatment titration or at the time of subsequent dose adjustment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Epilat Retard (Nifedipine Sustained-Release) by its potential for profound hemodynamic collapse and the inherent risk of delayed toxicity.

Documented Overdose Manifestations

Overdosage may present with profound hypotension (severe drop in blood pressure), disturbances of consciousness extending to coma, and severe heart rate abnormalities such as tachycardia or bradycardia. Documented physiological findings include hyperglycaemia, metabolic acidosis, and hypoxia. Serious outcomes listed in regulatory information include cardiogenic shock with pulmonary oedema and the potential for death.

Required Emergency Actions

Any suspected overdose mandates that the patient seek immediate medical attention. Due to the sustained-release formulation, the onset of severe symptoms can be delayed, requiring extended hospital monitoring even if the individual is initially asymptomatic. Management is focused on symptomatic and supportive treatment, as no specific antidote is known.

Population-Specific Notes

Regulatory documents highlight that overdose in children can lead to rapid cardiovascular collapse. Similarly, advanced age is recognized as a factor associated with poor prognosis in toxicity.

Therapeutic Uses of Epilat Retard

What Epilat Retard Treats: Main Uses and Benefits

Epilat Retard (Nifedipine Sustained-Release) is a medication generally used for managing chronic conditions that present with systemic or localized discomfort, primarily focusing on managing sustained vascular resistance and related symptoms that interfere with daily functioning. In clinical practice, the medication is used to help with high blood pressure and to manage angina (chest pain).

The medication is commonly used to help with the management of sustained elevation in systemic blood pressure, and is relevant in clinical settings involving recurrent chest discomfort (angina). It is also applied when symptoms arise from severe, episodic constriction of peripheral blood vessels, such as in Raynaud's Phenomenon.

The formulation contributes to the management of these episodes, which contributes to improved comfort and assists with maintaining functional stability. The sustained release formulation may help maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Support for Symptoms in Angina and Chronic Hypertension Epilat Retard is commonly used across conditions presenting with sustained elevation in systemic blood pressure and recurrent chest discomfort. It provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability for patients with stable cardiac ischemia or chronic hypertension.

Eligibility and Restrictions for Use

Who Can and Cannot Use Epilat Retard?

Epilat Retard (Nifedipine Sustained-Release) is a medication with specific population eligibility rules defined by government regulatory authorities. Use is primarily established and allowed for adult patients (aged 18 years and older) who do not have any listed contraindications.

Absolute Contraindications (Must Not Be Used)

Official labeling contraindicates the use of this medicine in specific groups due to unacceptable risk, including:

Patients with a known hypersensitivity to Nifedipine or other dihydropyridines.
Individuals in cardiogenic shock, with unstable angina pectoris, or within four weeks of an acute myocardial infarction.
Patients taking the medication Rifampicin concurrently.
In some regulatory regions, women who are pregnant or may become pregnant.

Conditional Use and Population Restrictions

Population Group	Regulatory Status
Pediatric Patients (Under 18)	Not approved; safety and efficacy have not been established.
Severe Hepatic Impairment	Requires careful monitoring and possible dose reduction due to altered drug clearance.
Breastfeeding Mothers	Not recommended as the substance is excreted into breast milk.
Severe Gastrointestinal Narrowing	Caution advised for the sustained-release formulation.
Poor Cardiac Reserve	Use may be restricted or subject to regulatory warnings.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Epilat Retard (Nifedipine) is subject to specific interaction rules defined by regulatory bodies, primarily involving the Cytochrome P450 3A4 (CYP3A4) enzyme system and pharmacodynamic effects.

Formal Contraindicated Combinations

Co-administration with potent CYP3A4 inducers, such as Rifampin, is formally contraindicated because these substances cause a significant reduction in Nifedipine plasma concentrations, compromising its therapeutic efficacy. The herbal product St. John’s Wort is also restricted for this same reason.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substances/Category	Documented Outcome
CYP3A4 Inhibition	Azole antifungals (e.g., Itraconazole), Macrolide antibiotics	Significantly increases Nifedipine systemic exposure (AUC and Cmax).
Additive Effect	Beta-Adrenergic Blocking Agents, other antihypertensives	Increased risk of severe hypotension due to combined blood pressure lowering.
Exposure Alteration	Digoxin	May result in elevated serum Digoxin concentrations.

Food and Timing Constraints

The ingestion of Grapefruit or Grapefruit Juice must be avoided, as it significantly increases Nifedipine exposure via CYP3A4 inhibition in the gut wall. For patients taking Nifedipine who are scheduled for surgery requiring high-dose Fentanyl anesthesia, regulatory documents advise allowing at least 36 hours for drug washout to minimize the risk of severe hypotension.

Mechanism of Action

Epilat Retard (Nifedipine) influences systemic vascular dynamics via a molecular cascade that results in arterial relaxation.

Ca^2+ Channel Blockade and Vascular Tone Regulation

The drug functions by acting as a selective inhibitor of the L-type Voltage-Dependent Calcium Channel (CaV1) . This targets the influx of Ca^2+ ions, which are the primary molecular trigger for smooth muscle contraction, particularly in the arterial walls. By interrupting this ion flow, the drug prevents the signaling cascade necessary for the muscle to shorten, leading directly to arterial vasodilation.

Systemic Effect: Reduction of Peripheral Resistance

The widespread relaxation of arterial smooth muscle decreases peripheral vascular resistance, a consequence resulting in afterload reduction. The sustained-release ("Retard") formulation modulates the rate of drug delivery, which reduces the rapidity of vasodilation and mitigates the intensity of the compensatory baroreceptor reflex and its resulting reflex tachycardia. This action results in a sustained reduction of vascular resistance.

Dosage and Administration Information

Instruction Map: How to Use Epilat Retard — Official Administration Guidelines

This map details the administration and dosing principles for Nifedipine Sustained-Release tablets.

Administration Scope

Instruction	Detail
Route of Administration	The approved route is Oral.
Dosing Schedule (Adults)	Initial dosing is generally 30 mg or 60 mg once daily, with the usual maintenance range being 30 mg to 90 mg once daily. Doses may be increased gradually every 7 to 14 days. Maximum doses range up to 120 mg per day for some formulations.
Timing in relation to meals	Some formulations instruct administration on an empty stomach or without food (1 hour before or 2 hours after a meal). Concurrent consumption of grapefruit juice must be avoided.
Age-Group Rules	Older adults may require a lower initial and maintenance dose. The safety and effectiveness of this formulation have not been established in patients younger than 18 years.
Population Adjustments	For patients with hepatic impairment, careful monitoring and a dose reduction may be necessary due to altered metabolism. Dosage adjustment is generally not required for renal impairment.

Instruction Classifications

Classification	Detail
Administration Method Type	Oral (sustained-release tablet).
Frequency Pattern	Once daily (q.d.).
Use-Context Constraints	The tablet must be swallowed whole and must not be crushed, chewed, or divided, as this compromises the controlled-release system. The inert outer shell may be observed in the stool after the drug has been absorbed.
Course Duration	Treatment is typically part of a long-term plan for chronic, stable conditions; discontinuation, if necessary, should involve a gradual dose reduction.

Connection to the Overall Use Protocol

Instructions establish a protocol for oral intake that protects the modified-release mechanism by prohibiting any alteration to the tablet. This governs the once-daily frequency and defines the required gradual dose titration schedule over specific time intervals. These rules formalize the precise parameters for the drug’s administration, including restrictions related to grapefruit juice and hepatic status.

Recent Clinical Evidence

Epilat Retard: Recent Clinical Evidence

Research focused on studying the active substance (nifedipine extended-release) and its use in managing conditions such as hypertension and certain cardiac conditions. This modified-release formulation was developed to provide a sustained profile, which is associated with a slower onset of action compared to immediate-release forms.

Core Efficacy and Comparative Studies

Studies have examined outcomes over extended periods, with large-scale Phase III trials reporting on changes in blood pressure over six-month treatment courses. Researchers also investigated whether the investigational compound was associated with changes in mobility in specific patient populations.

Formulation Comparison: Pharmacokinetic studies have addressed how the sustained-release mechanism affects drug absorption, particularly when compared to immediate-release formulations. Research also examined potential differences in outcomes between the retard formulation and monotherapy in certain patient groups, though findings regarding clinical significance were mixed.

Long-Term Safety and Special Populations

Long-term observational follow-up studies have monitored the incidence of events in patients. Research examined outcomes related to gastrointestinal discomfort and regularly included monitoring of liver enzyme levels to investigate the potential for hepatic events. Findings were evaluated over periods up to two years, with one study noting an elevation in a small subset of participants.

Pediatric and Adolescent Data: Studies in adolescents reported findings related to the amounts studied and the safety profile over a three-month period. Clinical evidence from a meta-analysis addressed the frequency of complications in certain conditions, with researchers studying outcomes over extended periods.

Frequently Asked Questions (FAQ)

Common questions about Epilat Retard (FAQ)

Q: What does the "Retard" part of Epilat Retard mean for the medicine’s release?

According to official product information, the term 'Retard' signifies that this is a sustained-release or extended-release formulation. This special design means the active medicine is released slowly and gradually into the body. This controlled delivery is meant to prolong the drug’s effects for sustained action.

Q: How is Epilat Retard different from immediate-release nifedipine?

The primary difference is the duration of action and frequency of dosing. The Retard formulation is designed to be taken once a day to maintain more stable medicine levels. Immediate-release forms are typically taken more frequently throughout the day.

Q: Are headaches a common side effect when starting Epilat Retard?

Yes, headache is a common side effect of this medicine, as listed in official regulatory documents. Safety information indicates that adverse effects are most likely to occur when treatment is first started or when the dosage is adjusted upward.

Q: Why do some patients experience swelling in their ankles or feet with this medication?

Swelling of the ankles or feet, known as peripheral edema, is a common side effect. This is related to the drug's intended action of relaxing and widening the blood vessels (vasodilation).

Q: Are there any known long-term side effects associated with Epilat Retard?

The long-term safety of the medicine has been monitored, with observational studies conducted over periods of up to two years. The documented risk profile, which lists common and uncommon adverse events, is available for the duration of treatment.

Q: Are there research studies available regarding the use of Epilat Retard in children?

Official regulatory information states that the safety and effectiveness of this extended-release formulation have not been established for patients under 18 years old. Therefore, the medicine is not formally approved for use in the pediatric population.

Q: Does Epilat Retard have a maximum recommended daily amount?

Regulatory documents specify a maximum daily amount for the extended-release formulation. Official documents reference different maximum daily amounts depending on the specific product formulation.

Q: Can Epilat Retard be taken at any time of day?

The extended-release tablet is meant to be taken once daily. To ensure consistent levels of the medicine in the body throughout the day, official guidance recommends maintaining a consistent daily schedule.

Q: What kind of pre-existing heart conditions might prevent someone from using Epilat Retard?

Official labeling lists specific absolute contraindications related to heart health, including cardiogenic shock, unstable angina, and a recent (within four weeks) acute myocardial infarction. Furthermore, caution is officially advised for patients who have poor cardiac reserve.

Q: Is Epilat Retard used to treat any other conditions besides high blood pressure and angina?

According to formal regulatory indications, the medicine is used for the treatment of high blood pressure (hypertension) and a specific type of chest pain known as chronic stable angina.

Q: Is feeling dizzy or lightheaded a common concern with Epilat Retard?

Dizziness is officially listed as an uncommon side effect, potentially affecting up to 1 in 100 people. Lightheadedness is a symptom that may be associated with low blood pressure (hypotension), which is also documented as an uncommon side effect.

Q: Can Epilat Retard affect bowel movements, such as causing constipation?

Yes, constipation is listed in regulatory safety documents as a common side effect of the medicine (may affect up to 1 in 10 people).

Q: Why do I feel more tired when taking Epilat Retard?

Fatigue, or feeling tired, is documented in regulatory safety information as a reported side effect of this extended-release formulation.

Q: Is it common to see the tablet shell in stool when taking Epilat Retard?

The official product information confirms that the inert outer shell of the tablet may be visible in the stool. This is a normal and harmless result of the controlled-release system, indicating that the medicine has been absorbed.

Q: Can taking Epilat Retard cause changes to the gums?

Swelling and tenderness of the gums, known as gingival hyperplasia, are documented in the safety information. This is listed as a possible, though less common, side effect.

Q: What happens if Epilat Retard is taken with alcohol?

Taking the medicine with alcohol may increase the blood pressure-lowering effect of the drug. This could increase the risk of side effects such as headache, dizziness, or fainting, according to regulatory documents on interactions.

Q: Is Epilat Retard known to interact with other common blood pressure medicines?

Regulatory documents confirm that the medicine can interact with other blood pressure treatments, such as beta-blockers. This combination can lead to an additive effect that increases the risk of severe hypotension, or very low blood pressure.

Q: What should be done if a dose of Epilat Retard is missed?

Regulatory documents describe a protocol where a missed dose may be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. Official information indicates that a double dose must not be taken to compensate for the missed one.

Q: Are muscle cramps or joint swelling listed as possible side effects of Epilat Retard?

Muscle cramps are documented in regulatory safety information as a less common reported side effect. While swelling of the ankles and feet (peripheral edema) is common, joint swelling is not specifically listed by that term.

Q: Can patients with diabetes take Epilat Retard?

Diabetes is listed in official product documents as a pre-existing medical condition that a healthcare professional should be aware of when prescribing the medicine.

Q: What are the different strengths that Epilat Retard is available in?

Extended-release tablets of the medicine are commercially available in several documented strengths. These commonly include various concentrations of the active ingredient.

Q: What is the expected duration of treatment with Epilat Retard?

Regulatory documents indicate that treatment with this medicine is typically designated as part of a long-term plan for chronic, stable conditions. Treatment is usually ongoing unless a healthcare provider determines that it should be discontinued, which often involves a gradual dose reduction.

Q: How long does the medicine stay in the body after a patient stops taking Epilat Retard?

The time it takes for the medicine to be eliminated is documented in pharmacokinetic data. The elimination half-life for the extended-release formulation is approximately 7 hours.

Q: Is there a warning about using Epilat Retard with a very low blood pressure?

The official label includes a specific warning about the risk of Excessive Hypotension, or very low blood pressure. This risk is emphasized, particularly during the initial phase of starting treatment or following any change in the dosage.

How should Epilat Retard be stored and disposed of?

Storage Conditions

The medicine must be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F), with limited excursions permitted to 15 C to 30 C (59 F to 86 F).

To ensure the stability of the extended-release formulation, the product must be protected from light and excessive moisture. Keep the tablets in their original container and ensure the container is tightly closed when not in use. Store the medicine in a location away from excessive heat and humidity, such as the bathroom, and keep it from freezing.

Child-Safety and Disposal

This medication must be secured and kept out of the reach of children.

Disposal of unused or expired Epilat Retard should be conducted according to local regulations. The best option is typically a drug take-back program. The tablets should not be flushed down the toilet or poured into a drain unless instructed to do so by an authorized source.

Epilat Retard